Flagship Pioneering’s Senda Bio secures $123M for new ‘programmable medicines’
Biotech startup Senda Biosciences is developing technology that yields a new type of medicine with two programming components: one directs the therapy to go to […]
biopharma nl
Don’t wait until it’s too late: Now’s the time to leverage cybersecurity standards for the production environment
Today’s factory floors include production equipment that’s linked directly into those IT systems that are so often the victims of a cyberattack. This “operational technology” […]
Merck picks circular path to RNA and commits $250M to biotech startup Orna
Merck aims to bolster its genetic medicines pipeline through a new research alliance with Orna Therapeutics, a startup whose technology forms RNA into a circle […]
Gilead claims breast cancer trial win but offers few details; drug application is filed with FDA
Gilead Sciences said it has statistically significant and clinically meaningful data from a pivotal test of its cancer drug, Trodelvy, in the most common type […]
Current advancements in wet AMD are not enough
AMD in particular impacts as many as 11 million Americans. About 15% of those affected have neovascular or wet AMD. It’s a devastating disease that […]
AstraZeneca & Daiichi drug wins another FDA approval, this time in lung cancer
On the heels of receiving a landmark FDA approval in breast cancer, AstraZeneca and Daiichi Sankyo drug Enhertu won an additional approval in non-small cell […]
Novartis warns of two patients deaths after dosing with gene therapy Zolgensma
The two deaths reported following treatment with Novartis’s Zolgensma mark the first fatal cases of acute liver failure associated with the gene therapy. Liver complications […]
340B entities face increased challenges in a shifting regulatory and enforcement landscape
Concerns about who qualifies under the 340B Program, how drugs can be dispensed to patients, and how much entities will be reimbursed may significantly impact […]
After RNA therapy falls short in the eye, ProQR Therapeutics pivots to liver, CNS
RNA therapies developer ProQR Therapeutics is eying a future without ophthalmology. After receiving European Medicines Agency feedback for its lead program for a rare eye […]
BMS reports data that could give its cell therapy an edge over rival J&J product
Bristol Myers Squibb has data showing that its multiple myeloma treatment Abecma beat the standard of care, preliminary Phase 3 results that could support moving […]
Aduhelm’s loss is a win for value-based drug pricing
Value-based pricing could have shown us with more certainty the real level of effectiveness of Aduhelm. Maybe it is worth paying something for; and value-based […]
Merck turns to biotech Cerevance to feed neuro pipeline with Alzheimer’s drugs
Merck is paying $25 million to kick off a research partnership with Cerevance, a startup that analyzes donor brain tissue to find novel targets for […]
GSK pays $100M to partner on a cancer drug with new twist on immunotherapy
GSK is partnering with Mersana Therapeutics on the development of an antibody-drug conjugate that is approaching Phase 1 testing. Unlike other ADCs that deliver a […]
FDA approval of AstraZeneca drug is first for a new group of breast cancer patients
Enhertu, a breast cancer drug from AstraZeneca and Daiichi Sankyo, is now FDA approved for treating patients whose tumors express low levels of the protein […]
Amgen’s $3.7B ChemoCentryx acquisition adds a new piece to autoimmune strategy
Amgen’s drug portfolio boasts several biologic drugs that are blockbuster sellers. In acquiring ChemoCentryx for $3.7 billion, the pharmaceutical giant gains a company entirely focused […]
Disappointing data lead Pfizer to drop heart drug acquired as part of $11B deal
Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was […]
The power of digital ecosystems to improve pharma supply chain operations [Sponsored]
A panel discussion from a recent Microsoft summit offered insights on how tech companies are closely collaborating with the pharma industry as they seek to […]
Ipsen’s latest R&D alliance brings novel T cell-activating drugs for cancer
Ipsen has been an active dealmaker lately, and it just struck another one that takes the pharmaceutical company into a new area of drug research. […]
Aiming to bring drug combos into earlier lines of cancer therapy, IDRx lands $122M
Taking inspiration from the success of drug cocktails that halt viral infections, startup IDRx aims to develop cancer drug combinations that stop tumor escape. The […]
Digital transformation: Reimagining clinical trial management [Sponsored]
Decentralized clinical trial approaches helped the pharma industry navigate through Covid-19. Now it is becoming increasingly clear that there’s a need for a hybrid approach […]
FDA hits pause on Beam Therapeutics’ off-the-shelf cell therapy for blood cancers
Beam Therapeutics’ application to begin human testing of a cell therapy made with base-editing technology is now under an FDA clinical hold. In other clinical […]
Novartis, UC Berkeley-spawned startup snags $65M to keep key proteins out of the cell’s trash can
Vicinitas Therapeutics is developing small molecule drugs that stabilize key proteins, preventing them from going to a cell’s built-in disposal system. The startup, which stems […]
U.S. government places $1.74B order for Moderna’s new Covid-19 vaccine boosters
The U.S. government has signed a supply agreement securing 66 million doses of Moderna’s Covid-19 vaccine booster shots, which are designed to address the omicron […]
Health equity should start at birth
Pregnant women and others able to give birth are severely underrepresented in clinical research globally. But real-world data – when relevant, reliable, and fit for […]
Is the HIF-PHI class of next-generation kidney drugs doomed in the U.S.?
Kidney disease patients need access to innovative therapies to expand treatment choices and improve quality of life. The FDA should closely examine whether it is […]
DOJ charges dozens for $1.2B in telemedicine fraud scheme
The charges involve some of the first cases in the country involving fraudulent cardiovascular genetic testing, a “burgeoning scheme,” according to a news release from […]
Elevating patient care from the home
By adding adherence and connectivity capabilities to home-based solutions, clinicians can maintain open lines of communication with patients, helping patients better care for themselves from […]
Lowering insulin prices isn’t the (only) answer to helping patients with diabetes
It is time to shift the conversation, incentives, and policy solutions to help people improve their health and get off of medications—not just make them […]
Reimagining healthcare in a quantum era
With promises of more efficient and reliable diagnoses, future breakthroughs in personalized medicine and targeted therapeutics, and an expedited R&D lifecycle, industry leaders must be […]
Novartis turns to algorithms developer Anumana to apply AI to cardio conditions
Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases. The goal is to find ways to detect […]
FDA delay means BeiGene, Novartis must wait longer for cancer drug decision
The FDA has deferred a regulatory decision on an esophageal cancer drug from partners BeiGene and Novartis, citing the need to complete inspections of the […]
Monoclonal antibodies are the way out of the Covid-19 pandemic
Whether they are acting as a therapeutic or preventive treatment, monoclonal antibodies can allow us to help contain the virus, where we might see the […]
New York AG: Teva USA’s parent company shouldn’t be allowed to escape opioid liability
Without the parent company, there’s concern Teva won’t be able to pay billions in reward to NY state.
Why stigma continues to exacerbate the United States’ drug epidemic
Since we know the fundamental causes of the opioid epidemic, why are we still here? It all centers around stigma.
Neuro startups form latest group of grads from PharmStars digital health accelerator
PharmStars, a digital health accelerator, graduated its latest cohort of startups, each of them developing a solution addressing some aspect of neurological disease. The accelerator […]
Areteia gets $350M to turn failed ALS drug into a therapy for severe asthma
New company Areteia Therapeutics launched with up to $350 million in financing and an asthma drug candidate from Knopp Biosciences. That drug, dexpramipexole, previously failed […]
Roche pays $55M for late-stage drug for rare kidney disease with no approved treatment
An Ionis Pharmaceuticals drug has positive Phase 2 results in immunoglobulin A nephropathy, leading Roche to exercise its option to license the rights to the […]
Vertex builds up pipeline of type 1 diabetes cell therapies with $320M buyout
Vertex Pharmaceuticals already has a cell therapy candidate for type 1 diabetes but the company says acquiring rival ViaCyte will provide it with complementary assets […]
Pfizer, BioNTech Covid-19 vaccine gets full FDA approval for adolescents
The FDA has granted the Pfizer and BioNTech Covid-19 full approval for use in adolescents. In other Covid-19 news, pharmacists were granted additional prescribing powers […]
AbbVie & Alector drop Alzheimer’s med from alliance, shifting focus to a 2nd drug
AbbVie paid Alector $205 million up front five years ago to begin an R&D partnership on two drugs intended to bring an immunotherapy approach to […]
FDA says pharmacists can prescribe Covid treatment
The AMA believes physicians should still be the main prescribers, while advocates for provider status for pharmacists say it’s a win for health equity and […]
Amgen joins Kernal Bio’s $25M financing as the startup brings mRNA 2.0 to cancer
Kernal Biologics has technology that enables the delivery of messenger RNA therapies to a wider range of destinations in the body. The Series A financing […]
W. Va. judge sides with drug distributors in bellwether opioid trial
From 2001 to 2017, the fatal overdose rate in Cabell County increased from 16.6 to 213.9 per 100,000. Judge finds no evidence of causation.
After initial failure, Intercept Pharma feels new data can get NASH drug approval
Two years after the stinging FDA rejection of its drug for the fatty liver disease NASH, Intercept Pharmaceuticals has more safety and efficacy data from […]
How Pfizer won the pandemic, reaping outsize profit and influence
Because the virus keeps mutating and will be around for a long time, the market for Pfizer’s products won’t go away. In wealthier countries, the […]
With new gene therapy data in hand, Sarepta talks with FDA about approval pathways
Sarepta Therapeutics has more clinical data showing the safety and efficacy of its experimental gene therapy for Duchenne muscular dystrophy. A pivotal Phase 3 test […]
How the agile in pharma trend is transforming drug development [Sponsored]
Emergn Principal Consultant Mario Moreira shared insights on how pharma companies can use the principles of Value, Flow and Quality to shorten drug development timelines […]
CureVac sues BioNTech, claiming Covid-19 vaccine infringes key mRNA patents
Messenger RNA vaccine biotech CureVac is suing BioNTech, alleging that its rival’s Covid-19 vaccine infringes on intellectual property built on more than two decades of […]
Novartis pays $100M to get Mallinckrodt’s ticket for a speedier FDA drug review
Novartis is acquiring an FDA priority review voucher from Mallinckrodt Pharmaceuticals. The $100 million price tag is in the neighborhood of the going rate for […]
As M&A costs rise, new Accenture report offers alternative strategies
Rising deal premiums and shrinking profit margins are threatening the sustainability of the traditional approach to mergers and acqusitions, according to a report by Accenture. […]
Liver injury leads FDA to pause Sanofi’s tests of MS drug acquired in $3.7B deal
The FDA placed a partial clinical hold on late-stage tests of Sanofi multiple sclerosis drug tolebrutinib after some patients developed drug-induced liver injury. While U.S. […]
Feds commit $3.2B to lock in Covid-19 vax supply ahead of fall vaccination campaign
New Covid-19 vaccine booster shots are coming and they’ll likely include protection against the omicron variant. The U.S. government agreed to a purchasing contract covering […]
Two for two: Sanofi snares twin European nods for enzyme replacement therapies
Sanofi won European Commission approval for two therapies that treat rare enzyme deficiencies. Xenpoyzme is the first treatment for acid sphingomyelinase deficiency (ASMD) while Nexviadyme […]
Ipsen’s $247M Epizyme acquisition brings approved cancer drug & more in pipeline
Ipsen is paying $247 million to acquire Epizyme, a cancer drug developer with one FDA-approved product: follicular lymphoma therapy Tazverik. The drug is a modest […]
Thought partnerships: The new frontier of client-agency partnerships
With emerging biotech needing help with a little bit of everything, these preferred partnerships can deliver a type of one-stop shopping leveraging an agency’s best […]
How small biotech companies can make the most out of today’s deal-making landscape
For small biotech companies that are always raising money, business development is a critical next step. Joining with a credible partner goes a long way […]
As muscular dystrophy drug meets key goal, Italfarmaco plans march forward to regulators
A Duchenne muscular dystrophy drug candidate from Italfarmaco Group has encouraging preliminary data from a pivotal study. The Milan, Italy-based pharmaceutical company says it now […]
New data for Intellia’s CRISPR therapy shows potential for one-time treatment of a rare disease
An Intellia Therapeutics therapy that uses CRISPR to perform in vivo genomic edits has clinical data showing that the therapeutic effects continue for a year […]
Biopharma firm Radius Health is going private in an $890M M&A deal
Two private equity firms have reached an $890 million deal to buy Radius Health, a company whose main asset is the commercialized osteoporosis drug Tymlos. […]
Novartis picks Precision Bio to bring in vivo gene editing meds to blood disorders
Novartis is paying Precision Bio $75 million up front to begin a partnership aiming to develop in vivo gene-editing therapies for serious genetic blood disorders, […]
AbbVie’s blockbuster drug Skyrizi gets FDA nod for treating Crohn’s disease
AbbVie drug Skyrizi is now approved for Crohn’s disease, making it the first treatment for the disorder that addresses a particular protein associated with inflammation. […]
Report: Whistleblower accuses CVS of “calculated and widespread” drug pricing scheme targeting elderly patients
CVS Health intentionally prevented certain Medicare beneficiaries from accessing less expensive, generic prescriptions, according to […]
Pfizer, Moderna Covid-19 vaccines are now authorized for kids as young as 6 months
Covid-19 vaccines from Pfizer and Moderna now have FDA emergency use authorization for children as young as 6 months old. If the Centers for Disease […]
Excited about investing in a promising early-stage healthcare company?
As a VC, if you start thinking about commercialization until after you’ve made the investment, then you’ll need a lot more than just good luck […]
November will bring political change. Will it also change drug prices and PDUFA?
Drug prices are on the minds of patients and politicians. The November election is expected to tip the balance of power in Congress and a […]
New study: The next pandemic is coming in hot. Here’s how we speed up life-saving research
Rapid and effective research is the only way to stave off massive loss of human life over the next 50 years. Fortunately, there are three […]
Tessa Therapeutics takes in $126M for cell therapies, and more biotech financings
Ten biotech companies were able to raise more than $500 million in combined financing in the past week. Here’s a recap of the funding activity, […]
A call to action for pharma manufacturers: Rise to the challenge of global medicine access with the help of digitalization
Operational efficiency and visibility brought on by digital transformation can help improve how pharmaceutical manufacturers do their critical part in improving equitable access and availability […]
Report: Deals continue downward slide for biopharma tech
During first three months of 2022, biopharma tech companies raised less money and made fewer dealsthan they did in the last three months of 2021. […]
GSK immunotherapy shows promise as alternative to surgery in certain rectal cancers
A small Memorial Sloan Kettering Cancer Center study found that all rectal cancer patients treated with GSK drug Jemperli showed a complete response at six […]
Roche bispecific drug Lunsumio lands European nod in follicular lymphoma
Follicular lymphoma patients in Europe now have a new treatment option. The European Commission approved Roche drug Lunsomio, a bispecific antibody designed to go after […]
ASCO recap: Breast cancer breakthrough, Mirati’s moves, Arcellx ascends & more
Breast cancer drugs and cell therapies were prominent in this year’s annual meeting of the American Society of Clinical Oncology. Here’s a recap of some […]
Biotech startup with AlphaGo-type AI approach snags $30M
The CEO of Anagenex believes that the company’s AI engine trained on billions of data points and iterative testing will blow other AI drug discovery […]
Code Bio corrals $75M to skip viruses, use synthetic DNA for genetic meds delivery
Code Biotherapeutics uses synthetic DNA as the foundation for its genetic medicines, which the startup claims offer several key advantages compared to genetic medicines delivered […]
Key metrics for successful D&I in the drug development lifecycle
Taking steps to eliminate health disparities among people of color and ensuring diversity throughout the development cycle should be a strategic goal for all. Medical […]
Becton Dickinson buys into pharmacy automation with $1.5B Parata acquisition
Becton Dickinson is getting into pharmacies with a more than $1.5 billion acquisition of Parata Systems, maker of robotics technologies that automate pharmacy tasks. The […]
Drug-industry survey blames insurer practices for barriers to care
Pharma companies often take the blame for high prescription costs. But a new, industry-sponsored survey shifts attention to insurance industry practices.
Repare relinquishes cancer drug to Roche, gets $125M to finance growing pipeline
Roche’s deep oncology pipeline is adding a drug candidate from Repare Therapeutics that works by interfering with a DNA repair mechanism of cancer cells. Repare […]
Digital endpoints: Global opportunities and clinical, data protection and other challenges
In December, the FDA published a draft guidance providing its recommendations on the use of digital health data acquisition in clinical investigations, signaling that regulatory […]
Covid-19 roundup: Boosters for kids, CAR-NK cell therapy, Paxlovid rebound & more
Pfizer and BioNTech reported positive clinical data for a Covid-19 booster in children younger than 5, results released ahead of a June FDA advisory committee […]
It’s time to integrate liquid biopsy into colorectal cancer treatment decision-making
Since it measures the total amount of circulating DNA (ctDNA) in a patient’s bloodstream using a simple blood draw, ctDNA liquid biopsy tests offers oncologists […]
What has Covid-19 taught us about virtual clinical trials?
At the upcoming INVEST PharmaTech virtual conference scheduled for July 26, the conversations will span myriad topics at the intersection of digital health and drug […]
Innoviva’s Entasis acquisition brings a novel antibiotic that’s ready for the FDA
Entasis Therapeutics is being acquired by Innoviva in a deal that brings an FDA-ready antibiotic developed to address drug-resistant strains of a bacterium that infects […]
CAR T without the toxicity: Kelonia gets $50M for a new take on cell therapy
Kelonia Therapeutics is developing cell therapies made by the in vivo engineering of a patient’s cells made possible by the targeted delivery of a genetic […]
FDA sounds caution on Foghorn cancer drug with a partial hold after patient death
The lead cancer drug candidate of Foghorn Therapeutics is now under a partial clinical hold following a patient death. According to the biotech, the patient […]
House Energy and Commerce Committee passes bill outlining FDA procedures to withdraw a drug
To withdraw a drug from the market, the FDA will have to provide the drug sponsor with notice and an explanation as well as the […]
Enanta RSV drug fails a Phase 2 test, but studies continue in higher-risk patients
An antiviral that Enanta Pharmaceuticals is developing for respiratory syncytial virus infection failed to beat a placebo in its first Phase 2 test. But the […]
INVEST Pitch Perfect winner: Modality.ai makes Tina the Alexa of clinical trials
Modality.ai has developed a conversational AI system that replaces in-person interviews that are part of neurological assessments for a range of disorders. The startup was […]
Clover Therapeutics turns a new leaf as Character Bio to pursue dry AMD & more
Dry age-related macular degeneration currently has no FDA-approved treatments but the research of Clover Therapeutics has yielded two candidates. The biotech startup has made progress […]
To focus on cancer, Chimerix sells rights to antiviral drug that defined the biotech
Chimerix is selling global rights to smallpox drug Tembexa, the biotech’s only FDA-approved product, as a way to fund clinical development of a therapy in […]
Claiming Akebia agreement breach, Otsuka seeks to end anemia drug pact
Otsuka Pharmaceutical is ending its alliance with Akebia Therapeutics, a move that comes less than two months after the FDA rejected their partnered anemia drug, […]
BMS builds on BridgeBio alliance, inking deal for rights to KRAS cancer drug
Bristol Myer Squibb is getting rights to BBP-398, a contender in the chase for drugs that address difficult-to-target KRAS mutations. Meanwhile, BridgeBio Pharma receives some […]
Startup Nuvig Therapeutics gets $47M to bring immune system back into balance
Nuvig Therapeutics is developing drugs that tap into one of the body’s natural mechanisms for controlling inflammation. Co-founder and CEO Pamela Conley, a veteran of […]
Regulatory recap: J&J vaccine limits, full Enhertu approval, a Vertex hold & more
The FDA amended emergency authorization of Johnson & Johnson’s Covid-19 vaccine. In other regulatory news this past week, drug approvals include a cancer drug that […]
Novel drug-discovery approach lands big backers
UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare diseases.
Biogen gets in tune with MedRhythms to develop new digital therapeutic for MS
Biogen struck a deal that could bring a digital therapeutic to its multiple sclerosis product portfolio. The drugmaker is partnering with startup MedRhythms in the […]
Study finds health system specialty pharmacies linked to reduced cost of care for MA patients
A study published in the Journal of Managed Care + Specialty Pharmacy found Medicare Advantage patients reduced their cost of care by using specialty pharmacies […]
California opens Medicaid to older unauthorized immigrants
Unauthorized immigrants over age 49 who fall below certain income thresholds are now eligible for full coverage by Medi-Cal, California’s version of Medicaid. If Gov. […]
FDA lifts Pfizer gene therapy clinical hold, but trial adds new safety measures
Pfizer now has the regulatory O.K. to resume pivotal tests of its gene therapy for Duchenne muscular dystrophy—but with new limitations and safety measures. The […]
Biohaven migraine drug partnered with Pfizer lands twin European approvals
The European Commission approved Biohaven Pharmaceuticals migraine drug rimegepant. While the regulatory decision marks another milestone for Biohaven, it’s also a win for Pfizer, which […]
Community welcomes President Biden’s call to action to rein in high drug prices
Now is the time for Congress to answer President Biden’s call to action and pass meaningful drug pricing reform that addresses the artificially inflated cost […]
AstraZeneca’s long-acting Covid-19 drug keeps protecting high-risk patients at 6 months
AstraZeneca’s Covid-19 antibody drug Evusheld reduced the risk of infection by 83% after six months. These results published in the New England Journal of Medicine […]
BMS joins Octant’s $80M financing and signs on as a drug discovery partner
Octant Bio’s synthetic biology approach to drug discovery is making progress, and the preclinical biotech has raised $80 million in Series B financing to continue […]
Regeneron captures new piece for cancer with $250M Checkmate Pharma buyout
Regeneron Pharmaceuticals is paying $250 million cash to acquire Checkmate Pharmaceuticals, a clinical-stage biotech developing drugs that activate the innate immune system. The biotech’s lead […]
Covid news roundup: Boosters for kids, breath diagnostic, a vax approval & more
Pfizer and BioNTech reported preliminary clinical data supporting use of their Covid-19 vaccine as a booster in children ages 5 to 11. In other Covid […]
BMS and Nektar end cancer drug alliance after two more clinical trial failures
Bristol Myers Squibb and Nektar Therapeutics are ending a cancer drug research alliance after data showed the combination of their respective drugs failed clinical trials […]
Cell therapy developer Be Bio hauls in $130M for pipeline in rare disease, cancer
Be Biopharma is developing cell therapies by engineering B cells to churn out therapeutic proteins with an initial focus on cancer and rare disease. The […]
CEO of upstart PBM: What CVS, Cigna and other PBMs are doing in drug pricing is neither sustainable nor ethical
A.J. Loiacono was speaking at MedCity INVEST in late March in Chicago when an audience member requested him to address whether it is sustainable to […]
FDA gives Gilead reprieve on partial hold for cancer drug studies
An FDA safety review has cleared Gilead Sciences to resume five clinical trials that were placed under a partial hold in January. The experimental Gilead […]
Aiming to make better mRNA vaccines, BioNTech strikes up alliance with Matinas
Oral delivery of messenger RNA is one of the capabilities of Matinas BioPharma’s technology. BioNTech will explore that feature among others under a new research […]
CA handed its Medicaid drug program to a company. Then came a corporate takeover.
California awarded the Medi-Cal Rx program to a unit of Magellan Health, a company with expertise in pharmacy benefits and mental health. But Magellan was […]
Werewolf cancer drug strikes right note with Jazz Pharma, sparking licensing deal
Jazz Pharmaceuticals is licensing rights to a Werewolf Therapeutics cytokine therapy that’s on track to reach clinical testing next year. The deal gives Jazz a […]
Pfizer broadens its RSV reach with deal for ReViral and its clinical-stage antivirals
Pfizer is already in the mix of companies pursuing vaccines for respiratory syncytial virus. The pharma giant is now broadening its scope with a deal […]
Imara’s two trial flops in blood disorders dim drug’s prospects in heart failure
The lead drug candidate of Imara failed two separate mid-stage clinical trials evaluating it in rare, inherited hemoglobin disorders. Imara had been planning to advance […]
FDA places partial hold on Curis cancer drug after patient death in clinical trial
The FDA placed a partial hold on a Curis drug in development for treating leukemia after a patient treated in a clinical trial died. The […]
The diagnostic dilemma of co-infections requires novel solutions
Metagenomics offers advances for infectious disease diagnostics by providing the diagnostic technology to detect a potentially unlimited numbers of known and novel microbes from a […]
Becton Dickinson spins off diabetes biz, enabling Embecta to embark on its own
The second quarter of 2022 kicked off with a new life sciences company joining the public markets, but not via an IPO or merger. Becton […]
Safety concerns sink Akebia drug for anemia from chronic kidney disease
The FDA rejected Akebia Therapeutics drug vadadustat as a treatment for anemia caused by chronic kidney disease. According to the biotech, the agency cited safety […]
Thread, AWS partner on next-gen tech for clinical trials
The partners aim to make decentralized clinical trials more efficient and less expensive through greater use of AI and machine learning.
At a Tennessee crossroads, two pharmacies, a monkey, and millions of pills
Federal prosecutors have unveiled a rare criminal case alleging that owners of a pharmacy in Celina, Tennessee intentionally courted opioid seekers by filling dangerous prescriptions […]
As cash keeps pouring into health startups, VC firms work to stay disciplined
Venture capital investment in healthcare startups is continuing at a steady pace. Is it too much? Is a correction coming? Three investors offered their perspectives […]
Data and regulatory roundup: Pfizer’s feat, an ADHD miss, Eli Lilly’s CRL & more
A pharmaceutical giant reported a Phase 3 success for a potential blockbuster drug, while four other companies reported disappointing data from their respective clinical trials. […]
AN2 Therapeutics’ IPO raises $69M to take antibiotic from Pfizer into pivotal test
AN2 is developing an antibiotic based on boron chemistry that could offer advantages over carbon-based molecules. The biotech plans to advance its drug candidate, licensed […]
Covid antivirals: How the last mile can save those at highest-risk
Fixing the last mile may not be as sexy as sprinting toward the development of the mRNA vaccines or our first anti-viral treatments, but addressing […]
Hearing is believing in clinical trials
The direct recording and analysis of voice ensures that a more diverse range of patients is represented in clinical trials. This is crucial for effective therapeutic […]
Ligand Pharma turns to a SPAC to take antibody biz public, raise up to $266M
OmniAb, the antibody division of Ligand Pharmaceuticals, is set to go public through a SPAC merger that will infuse the business with up to $266 […]
Celsius Therapeutics heats up with $83M and an IBD drug on path to the clinic
Single-cell analysis biotech Celsius Therapeutics has raised $83 million to advance its pipeline of drugs for autoimmune disorders and cancer. The startup’s lead autoimmune program, […]
Pfizer CEO pushes annual Covid shot, but experts disagree
When Pfizer CEO Albert Bourla said March 13 that all Americans would need a second […]
Study: Machine learning successfully tracks drugs stolen from hospitals faster and with minimal error
A retrospective study published in American Journal of Health-System Pharmacy found that machine learning and advanced analytics technology not only identifies drug diversion – when […]
Connecting the healthcare data dots: How a harmonized healthcare data strategy can create efficiencies
When the healthcare industry talks about data, the conversation usually focuses on interoperability and data standards. While these are certainly important, the most effective way […]
Precision oncology startup AnHeart Therapeutics co-founder shares cancer drug strategy
AnHeart Therapeutics is developing a pipeline of precision oncology therapeutics. Chief Business Officer and Co-founder Lihua Zheng provided an overview of company’s strategy in response […]
Zosano Pharma cuts staff 31%, the latest layoffs in a wave of biotech belt-tightening
Regulatory setbacks for a new migraine treatment have led Zosano Pharma to restructure, laying off about 31% of its staff. Zosano is one of several […]
Restoring trust in clinical trials among Black communities
Whether seeking to overcome ongoing hesitation of the Covid-19 vaccine or searching for moonshot cancer solutions, whatever the healthcare need demands, seeking results for diverse […]
Illumina Accelerator unveils 7 genomics startups selected for latest funding cycle
Illumina Accelerator has invested in 68 companies so far, all of them startups developing genomics technologies. Seven startups comprise the latest cohort selected by the […]
Biotech startup Eclipse Bio emerges to shed light on RNA drug research
Scientists developing new RNA drugs need to understand how proteins bind to these molecules. Eclipsebio’s technology provides that analysis and the biotech startup now has […]
RNA biotech Nutcracker Therapeutics unshells $167M for drugs built on biochips
ARCH Venture Partners led the Series C round of financing for Nutcracker Therapeutics, a company developing new RNA drugs. The company’s process for developing and […]
Modest activity, tolerability issues sink lead Harpoon cancer drug prospect
Harpoon Therapeutics is discontinuing work on its lead drug in prostate cancer following disappointing data in an early-stage clinical trial. Though Harpoon has other drugs […]
Novartis turns to Voyager Therapeutics to get gene therapies into the brain
Novartis is paying Voyager Therapeutics $53 million up front to begin a partnership focused on the discovery of capsids for central nervous system disorder gene […]
Bloomberg: Court docs reveal J&J’s role in prison tests comparing talc to asbestos
Research of Johnson & Johnson’s baby powder included a prison study in which inmates, mostly Black men, were injected with asbestos. The study was intended […]
FDA regulatory roundup: two approvals, three rejections & one clinical hold
The FDA approved drugs from Johnson & Johnson and CTI BioPharma in the past week. Complete response letters were issued to Gilead Sciences, Amryt, and […]
Princeton spinout ArrePath gets $20M to combine AI, imaging in antibiotics R&D
Anti-infective drug discovery startup ArrePath has launched with $20 million in seed funding to advance the development of molecules that use a dual mechanism to […]
Eli Lilly to stand trial over Medicaid rebate payments
A judge ruled the lawsuit against Eli Lilly for their Medicaid rebate payments will proceed to trial; Ely Lilly is accused of underpaying for Medicaid […]
Nonprofit drugmaker Civica Rx unveils plans for insulin biosimilars, $30 per vial
Civica Rx plans to make lower cost versions of three branded insulin products, biosimilars that are expected to reach the market in 2024. In addition […]
AbbVie makes neuro drug connection with $130M Syndesi Therapeutics acquisition
AbbVie has acquired Syndesi Therapeutics, an early clinical neuroscience startup developing drugs that have potential applications in a range of cognitive disorders. Syndesi is based […]
Sanofi and DarioHealth team up on digital health tools for chronic conditions
Sanofi and digital therapeutics company DarioHealth will work together to promote the tech firm’s offerings for the management of chronic diseases. Under the $30 million, […]
Which pharmatech startups will present at MedCity INVEST’s Pitch Perfect contest?
Five companies will present to a group of investor judges. They will be evaluated on criteria such as business idea, market opportunity, and revenue model.
A clarion call to improve mental health treatment post-Covid-19
Leveraging a precision prescribing platform with embedded genomic analysis will help physicians improve care and reduce costs by providing valuable information to inform mental health […]
Biocon expands portfolio & market reach with $3.3B buyout of Viatris biosimilars
Biocon Biologics is acquiring the biosimilars business of its longtime partner, Viatris. The deal gives Biocon a biosimilars presence in both emerging and developed markets, […]
Healthcare firms were pushed to confront racism. Now some are investing in Black startups.
The racial reckoning of the past couple of years has inspired many industries to take a look at their histories and practices.
Why the FTC’s recent decision to not study PBMs might hurt consumers and independent pharmacies
With its ruling to maintain the status quo, the FTC has decided to take a back-seat and force independent pharmacies to fend for themselves in […]
Kodiak Sciences’ trial failure clouds eye drug’s prospects for challenging Eylea
A Kodiak Sciences drug failed to beat a Regeneron Pharmaceuticals product in a key test in the wet form of age-related macular degeneration. The biotech […]
Cash woes at neuro biotech Yumanity lead to 60% staff cut and search for a buyer
Yumanity’s corporate restructuring means the biotech is now exploring “strategic alternatives” that could include a sale of the company or its assets. The biotech’s lead […]
J&J partners with startup Remix, aiming to treat disease by “tuning” RNA
Several biotech companies are rising to the challenge of developing small molecules to drug RNA. Remix Therapeutics is joining the chase, but its different approach […]
Solution to big gene therapy obstacle leads to Spain’s largest biotech Series A round
SpliceBio will use its €50 million in financing to advance development of a gene therapy for Stargardt disease, a rare eye disorder. The biotech’s technology […]
Alexa joins the site staff: how clinical trials tech will evolve in 2022
Expect more clinical trial sponsors to embrace these technologies as the industry sees wider adoption of decentralized clinical trials.
AI-biotech Terray emerges with $60M and a solution for data problems in drug R&D
Terray Therapeutics uses tiny microarrays to test molecules against targets of interest, then applies artificial intelligence to build large chemical datasets. The startup’s Series A […]
IQVIA report: Drug R&D reaches new highs, and not just for Covid-19 products
The biopharmaceutical industry continues to be a hotbed of activity, with more than 6,000 products in active development and a growing share of that innovation […]
Outlook dims for ProQR’s RNA therapy for vision loss following failure in key test
The lead RNA therapy from ProQR Therapeutics has failed the main and secondary goals of a pivotal study testing it as a treatment for a […]
Now is the time to tackle medication adherence in clinical trials
Integrating advanced technologies, including smart packaging and powerful data analytics, is driving a revolution in adherence monitoring that is accelerating drug development timelines, lowering clinical […]
Neuro-focused Arkuda raises $64M as dementia drug moves closer to the clinic
Eli Lilly is among the new investors joining the Series B round of Arkuda Therapeutics, a biotech developing a drug to treat a rare, inherited […]
Behind the scenes: The role data plays in getting new therapeutics to market
In a competitive market, data that help companies find these critical resources can accelerate clinical trials and shorten time to market – sometimes by years.
AI-driven Congruence Therapeutics gets $50M to stabilize misfolded proteins
Biotech startup Congruence Therapeutics is developing novel drugs that treat disease by stabilizing misfolded proteins. Key to the company’s approach is a computational platform that […]
Endeavor Bio adds $101M to test ex-Eli Lilly, Roche drug in cancer & lung fibrosis
Endeavor BioMedicines aims to kill two birds with one stone—that stone being a small molecule drug. Taladegib targets a cell signaling pathway associated with both […]
Unity Bio slashes headcount in half to save cash ahead of eye drug readouts
Unity Biotechnology’s corporate restructuring is a cash-saving move that allows the company to focus resources on its lead program, a drug in Phase 2 testing […]
Softbank leads Dewpoint’s $150M round as multiple programs march toward clinic
Dewpoint is developing drugs targeting biomolecular condensates, tiny droplets in cells that contain proteins and nucleic acids. Dysfunction of these organelles can play a role […]
Blue Cross settles class action suit naming ‘pharma bro’ Martin Shkreli for $28M
Shkreli controversially raised the price of the drug Daraprim, which is used to treat a potentially fatal parasitic infection, by 4,000%, from $13.50 to $750 […]
Digital collaboration here to stay beyond pandemic for Merck, Pfizer, others
A recent survey pulled medical affairs thought leaders and found that a majority see asynchronous virtual options in conjunction with in-person as the preferred path […]
Pfizer bows out of developing cardio drug, returns rights to Ionis Pharmaceuticals
Sometimes even a clinical trial where the endpoints have been met may not give the […]
Clinical trials startup comes out of stealth by announcing $27.5M funding round
Topography Health announced their 27.5M series A funding for their clinical trials technology led by Andreessen Horowitz and Bain Capital Ventures.
Three pharmacy trends that will define 2022
The pharmaceutical industry made more headlines in 2021 than in any other year in recent memory. And 2022 is set to be a monumental year […]
Foresite and GV pour $40M into startup’s move to CHIP into new disease biology
TenSixteen Bio has emerged from stealth aiming to develop drugs for diseases caused by genetic mutations accumulated as we age. The startup has been incubating […]
3 forecasts for the PBM industry in 2022
The current landscape heading into 2022 will keep pharmacy benefits under the microscope. Plan sponsors will evaluate their PBM’s pricing model to determine if their […]
Palliative care: An essential resource in caring for those with advanced illness
Palliative care must be the standard of care for all who have been diagnosed with progressive, advanced, and terminal illnesses. Never should we hear the […]
MedCity Pivot Podcast: A conversation with Stoke Therapeutics CMS regarding how to tackle Dravet Syndrome
Barry Ticho explains the novel drug that the company is developing to tackle Dravet Syndrome as well as how the company’s stock price decline isn’t […]
What is inflation’s impact on clinical trials?
Basic organic chemicals used for the preparation of new medications cost over 54.8% more than they did 12 months ago. Further, with schools and daycare […]
A new approach to managing surgical site infections: using multi-layer formulations in extended-release antibiotics
Physicians may soon have a solution that could be ideal for preventing surgical site infections with a combined multi-layered system that provides the surgical site […]
AI firm BenchSci raises $50M for tech that takes waste out of preclinical research
BenchSci’s technology uses artificial intelligence to make drug R&D faster and more efficient. Big pharmaceutical companies and clinical-stage biotechs are current users of the software, […]
Pfizer’s growth hormone deficiency drug comes up short at the FDA
The FDA has rejected Pfizer’s somatrogon, a long-acting form of human growth hormone designed for once-weekly dosing. The setback delays Pfizer and partner Opko Health […]
Kura Oncology leukemia clinical trial to resume after FDA lifts partial hold
The FDA placed the partial hold on the study last November following a patient death suspected to be linked to a known complication of leukemia […]
Psychedelic biotech Eleusis enters SPAC deal to take depression drug to the clinic
Eleusis is developing a formulation of the psychedelic compound psilocybin that overcomes limitations of pill versions of the drug. Depression is Eleusis’s lead disease target […]
ImmPACT Bio reels in $111M to prevent tumor escape with novel cell therapies
Despite the targeted approach of some cancer treatments, tumors can find ways to escape, leading patients to relapse. ImmPACT Bio will apply its Series B […]
J&J’s investment arm joins $150M investment in digital health firm Verana
Digital health company Verana Health has raised $150 million. The company said it will use the new capital to expand its technology, which is used […]
AstraZeneca bets $75M on Scorpion’s precision approach to tough cancer targets
AstraZeneca’s partnership with Scorpion Therapeutics will focus on transcription factors that are known to play a role in cancer but have been difficult to target […]
BeyondSpring is laying off 35% of staff in wake of FDA rejection of lead drug
BeyondSpring Pharmaceuticals’ corporate reorganization comes about six weeks after the FDA rejected the biotech’s drug for a complication experienced by cancer patients. The company still […]
Country’s largest pancreatic disease patient registry launches
The National Pancreas Foundation and Seqster are partnering to create a dynamic digital database for patients with pancreatic diseases that compiles patients’ data from genomic […]
Freenome gets $290M from Roche as it preps blood-based cancer test’s next steps
A month after Freenome closed $300 million in financing, Roche has invested another $290 million in the diagnostics developer. The cash infusion comes as Freenome […]
Pfizer, Bayer each strike up deals to add in-vivo gene editing to pipeline mix
As the annual J.P. Morgan HealthCare Conference kicked off Monday, two pharma giants unveiled deals that expand give them access to in-vivo gene editing technologies. […]
Startup Avenge Bio nabs $45M for novel cell therapy approach to ovarian cancer
The field of biotechs pursuing new interleukin-2 cancer immunotherapies is filled with companies engineering different versions of that signaling protein. Avenge Bio CEO Mike Heffernan […]
Amylyx Pharma’s IPO lands $190M as ALS drug begins FDA review
It’s the first week of the new year, and the life sciences sector continued the IPO momentum of 2021 as Wall Street welcomed three new […]
Sanofi bets big on AI again, paying $100M to start drug R&D pact with Exscientia
Sanofi’s new alliance with artificial intelligence biotech Exscientia spans up to 15 small molecule drugs in cancer and immunology. If drugs from the partnership reach […]
Sanofi’s overhaul of genomic medicines strategy spells end of Sangamo alliance
A Sanofi strategy shift is leading to the end of a gene-editing alliance with Sangamo Therapeutics. Though the partnership has produced encouraging early clinical data […]
Friendly fire: Using viruses to kill tumors and fight breast cancer
Oncolytic viruses have the power to make the tumor more visible to the immune system and mark the area of attack. It is this anti-tumor […]
Avrobio shifts gene therapy priorities as data surprise shelves lead program
Avrobio is stopping enrollment in a clinical trial for its Fabry disease program after new results showed variability in how the gene therapy was taken […]
Aetion acquires Replica Analytics to bring aboard synthetic data capabilities
Health analytics firm Aetion has acquired Replica Analytics, a company that specializes in synthetic data. Aetion said Replica will enable it to analyze previously inaccessible […]
Medical education through Twitter? Pharma’s digital strategy for healthcare providers [Sponsored]
“Most Q&As are happening on Twitter. If you’re not doing social listening you’re losing fresh insights into things like disease states.” That was just one […]
FDA expands Covid-19 boosters for kids using real-world data in much older adults
The FDA has expanded emergency authorization of Covid-19 boosters to include children 12 to 15 vaccinated with the Pfizer and BioNTech messenger RNA shot. The […]
Ovid Therapeutics adds to epilepsy drug pipeline with new AstraZeneca alliance
Ovid Therapeutics is acquiring global rights to AstraZeneca molecules that address a novel target to treat epilepsy. The AstraZeneca deal comes 10 months after Takeda […]
Cancer therapies lead way as FDA tallies 60 drug approvals in 2021
As in previous years, cancer products topped the list of new FDA-approved therapies in 2021. But the list of drug approvals is notable for other […]
Cell therapy, AI drug discovery highlight 2021’s record year in biotech IPOs
The biggest biotech IPO of 2021 belongs to a cell therapy developer that has yet to reach the clinic. Cell therapy and artificial intelligence were […]
Newly public Pardes Bio aims to show its Covid-19 pill can offer edge over Pfizer’s
Pardes Biosciences’ experimental oral antiviral for treating and preventing Covid-19 infection addresses the same target as Pfizer’s authorized pill Paxlovid, but with a potential dosing […]
Leo Pharma’s FDA nod adds a challenger to Dupixent’s dominance in eczema
With FDA approval for its atopic dermatitis drug Adbry, LEO Pharma will reach the U.S market ahead of an Eli Lilly atopic dermatitis drug that […]
Heart drug’s trial failure busts bid to best Pfizer, but BridgeBio still bets on coming data
BridgeBio reported its drug acoramidis missed the main goal of a pivotal study in patients with transthyretin amyloidosis affecting the heart—the same type of patients […]
FDA authorizes Merck antiviral, which joins Pfizer pill as oral option for Covid-19
Merck antiviral drug molnupiravir received emergency authorization, joining Pfizer’s Paxlovid as the only authorized oral antiviral drugs for treating Covid-19. Though the Merck and Pfizer […]
FDA nod for Novartis sets up cholesterol drug showdown with Amgen, Regeneron
Novartis drug Leqvio now has the FDA’s green light, making it the first RNA interference medicine approved for lowering cholesterol. The regulatory decision sets the […]
Patient death prompts FDA halt on Pfizer’s Duchenne gene therapy study
The FDA has halted tests of a Pfizer gene therapy for Duchenne muscular dystrophy. The clinical hold is one of several placed on gene therapy […]
Sanofi’s $1B Amunix acquisition aims for targeted, safer T cell engagers for cancer
In acquiring Amunix, Sanofi becomes the latest big pharmaceutical company to strike a deal to gain access to technology that improves the safety and efficacy […]
Novartis, BeiGene ink another deal; plan for tests of checkpoint cancer drug combos
Novartis is partnering with BeiGene on the development of a drug that addresses TIGIT, a hot cancer immunotherapy target. The Swiss pharma giant is committing […]
More than our stories: The do’s and don’ts of engaging patient advocates
What follows is guidance for healthcare workers, hospital administrators, journalists, nonprofit leaders, government officials, industry leaders, and others who want to invite engage a patient […]
Biogen slashes price of Alzheimer’s drug by half as CMS coverage decision looms
The price of Biogen Alzheimer’s disease drug Aduhelm will be cut in half at the start of 2022, a move that comes as a Medicare […]
Let’s focus on patient compliance as the problem, not adherence
The change in terminology from “compliance” to “adherence” is based on unfounded and untenable foundations. It conflates cause and effect, and a shift in language […]
FDA approval of Argenx neuromuscular disease therapy is first in new drug class
Myasthenia gravis patients now have a new FDA-approved biological treatment. Argenx drug Vyvgart provides a treatment alternative for patients who have the rare autoimmune disorder […]
Ipsen gets rights to failed Genfit NASH drug, now in Phase 3 for rare liver disease
Ipsen is paying €120 million up front to acquire global rights to elafibranor, a Genfit drug that fell short as a treatment for NASH, but […]
4 ways AI can transform clinical trials
We cannot simply accept that testing new drugs will continue to be a slow and expensive process. AI has the potential to disrupt the current […]
Eli Lilly joins Verge Genomics’ $98M round as AI-discovered ALS drug nears clinic
Three life science companies unveiled Series B rounds of funding Thursday, early Christmas gifts that top $219 million combined. Along with Verge Genomics, the other […]
Biogen projects confirmatory study for Alzheimer’s drug will take four years
Six months after Biogen was awarded regulatory approval for its Alzheimer’s disease drug Aduhelm, the company the company is laying out a timeline for the […]
Startup Mythic Therapeutics emerges with $103M to control fate of ADC cancer drugs
Antibody drug conjugates deliver a targeted strike to tumors, but the toxic payloads of these therapies can still reach healthy tissue. Mythic Therapeutics’ FateControl technology ensures […]
CSL shakes off pandemic woes, diversifies with $11.7B Vifor Pharma acquisition
CSL Limited makes many of its therapies from donated plasma, which posed a challenge as pandemic lockdowns led to a steep drop in plasma collections. […]
BMS joins off the shelf cell therapy chase with alliance on Immatics cancer drug
Bristol Myers Squibb is paying $150 million up front for global rights to an Immatics biologic drug designed to recruit a patient’s T cells to […]
As genetic testing expands, evidence and awareness needed to spur adoption
Genetic tests are becoming available for a wider range of applications. During a CB Insights panel discussion, Phil Febbo of Illumina and Alicia Zhou of […]
AstraZeneca’s long-acting antibody drug lands FDA authorization for Covid-19
FDA authorization of AstraZeneca drug Evusheld makes it the first antibody therapy for preventing infection before exposure to Covid-19, providing an option for immunocompromised patients […]
First cohort of digital health startups graduates from PharmStars accelerator
PharmStars, an accelerator for companies developing digital solutions for pharmaceutical companies, has graduated its first class of startups. The theme for this initial group was […]
Alzheimer’s disease should be approached as white matter disease, not gray
We now know how important white matter is to our overall brain health and cognitive ability, as well as how declines in white matter structure […]
Cancer & immunology biotech Odyssey embarks with $218M, Gary Glick at helm
Odyssey Therapeutics is the latest startup formed by serial biotech entrepreneur Gary Glick. Odyssey’s destination is oncology and immunology drugs that address novel disease targets, […]
Liberating real-world data for use in clinical trials
Liberating the genetics, laboratory and pharmacy data that sits deep within healthcare subsystems, while protecting patient information and navigating the global regulatory landscape, is no […]
Harvard spinout Nabla Bio lands $11M to bring AI technology to antibody design
Nabla Bio emerged from the lab of famed Harvard scientists George Church last year, and its antibody discovery technology has already led to five partnerships […]
Early clinical data validate rare immune cell for Adicet’s off-the-shelf cancer therapy
Adicet Bio makes its therapies from gamma delta T cells, a rare type of immune cell that the company believes offer advantages compared to other […]
Radiation and BOTOX: Harnessing the power of nature to advance medical discovery and treatment
What do radiation and Botox have in common? Two powerful tools that were tamed by medicine in the quest to help patients. We’ve found ways […]
Infants, kids now have a Covid-19 therapy as FDA expands use of Eli Lilly drug
Eli Lilly’s authorized antibody drug for treating and preventing Covid-19 infection in adolescents and adults is now authorized for pediatric patients, including newborns. While tests […]
Hospitals refused to give patients ivermectin. Lockdowns and political pressure followed.
Ivermectin and other unauthorized covid treatments have become a major source of dispute in recent months. Lawsuits over hospitals’ refusals to provide ivermectin to patients […]
With $100M ReCept M&A deal, Omnicell enters growing specialty pharmacy space
Specialty drugs represent a growing share of overall pharmaceutical sales, and Omnicell is acquiring specialty pharmacy technologies company ReCept Pharmacy to enter into this market. […]
Novartis boosts neuro pipeline through alliance on UCB Parkinson’s drugs
Novartis is paying UCB $150 million up front to share in the development of two clinical-stage Parkinson’s disease drugs that offer new approaches to treating […]
FDA turns down BeyondSpring chemo complication drug, asks for another trial
BeyondSpring Pharmaceuticals said the FDA wants another clinical trial to demonstrate patient benefit for its drug, a small molecule developed to treat a dangerous and […]
Sanofi makes another mRNA move with deal for skin microbiome biotech Origimm
Sanofi’s strategy to develop new messenger RNA vaccines is adding another piece. The pharmaceutical giant struck a deal to acquire Origimm Biotechnology, a startup developing […]
Children aren’t miniature adults — and deserve behavioral healthcare tailored specifically for them
For too long, we’ve forced kids to make do with services made for adults. The results have been nothing less than tragic, as evidenced by […]
After Phase 3 failure busts blockbuster bid, Deciphera restructures; staff slashed 35%
Deciphera Pharmaceuticals’ corporate restructuring will slash headcount by 35% and stop work on two drug programs. Going forward, the biotech said it will focus on […]
FDA study offers new tool to make sense out of pharmacogenetics data
Prescribers need a pharmacogenetics knowledge base to determine a safe and effective medication and dosage for their patients, but they also need pharmacogenetics test information […]
Cell therapy biotech Quell adds $156M for alternative to organ transplant meds
Quell Therapeutics’ $156 million Series B round comes as it prepares to advance to a clinical trial testing its lead regulatory T cell therapy candidate […]
Blueprint Medicines to buy cancer drug startup with potential edge over Takeda, J&J targeted therapies
Blueprint Medicines is paying $250 million up front to acquire Lengo Therapeutics, developer of targeted cancer therapies. The startup’s lead drug candidate is on track […]
Want the lowest-net-cost drugs? Change your thinking on disruption
When your organization asks for a lowest-net-cost formulary, what you’re really saying is, “I want the deepest contractual discounts aligned with my formulary without disruption.”
Concern about Covid-19 variant Omicron centers on spike protein mutations
The new Covid-19 variant, named Omicron, has mutations that could help it evade antibodies produced by the immune system. Scientists are conducting lab tests to […]
FDA hands out approvals to Takeda transplant drug, Aadi Bio cancer therapy
Takeda Pharmaceutical won FDA approval for Livtencity, an antiviral developed to treat cytomegalovirus infection in transplant patients. The agency also approved an Aadi Biosciences drug, […]
Neuro drugs dumped by AbbVie are now heading to Neurocrine for $100M up front
AbbVie returned the rights to the drugs to Sosei Heptares earlier this year. Now Neurocrine Biosciences has agreed to pay the Japanese drug company $100 […]
Vifor Pharma adds to chronic kidney disease lineup with pair of acquisitions
Nephrology products company Vifor Pharma is shelling out about $252 million combined up front to acquire Sanifit Therapeutics and Inositec, developers of drugs for a […]
BioMarin Pharma sees big things for first FDA-approved dwarfism drug
BioMarin Pharmaceutical’s Voxzogo is the first FDA approved therapy for achondroplasia, an inherited disorder that causes the most common form of dwarfism. With approvals in […]
Sanofi makes $270M bet that a startup’s AI tech can boost its cancer drug R&D
The sum represents Sanofi’s equity investment in Owkin, plus a payment to begin a research partnership covering four types of cancer. Meanwhile, Owkin said the […]
Generate Bio adds $370M for big push toward programmable protein medicines
Generate Biomedicines applies artificial intelligence and machine learning to protein analysis, which it uses to program its protein therapies for particular applications. The startup now […]
The emerging golden era of neuroscience [Sponsored]
Bill Martin, the Global Therapeutic Area Head of Neuroscience at The Janssen Pharmaceutical Companies of Johnson & Johnson, shared some of the promising developments in […]
Novo Nordisk reaches $3.3B deal to acquire RNAi partner Dicerna Pharma
The acquisition agreement comes exactly two years after the two companies began a wide-ranging alliance focused on developing RNA interference drug for metabolic disorders. The […]
RA Capital reveals next play in protein degradation, this time outside the cell
The first wave of biotechs developing drugs that employ targeted protein degradation target disease-causing proteins inside the cell. Biotech startup Avilar Therapeutics, formed by RA […]
Aiming for on/off switch of genes, Chroma corrals $125M for new wave of medicines
Chroma Medicine is developing epigenetic therapies that turn genes on or off. The biotech startup has emerged from stealth mode backed by a $125 million […]
English
Afrikaans
Shqip
አማርኛ
العربية
Հայերեն
Azərbaycan dili
Euskara
Беларуская мова
বাংলা
Bosanski
Български
Català
Cebuano
Chichewa
简体中文
繁體中文
Corsu
Hrvatski
Čeština
Dansk
Nederlands
Esperanto
Eesti
Filipino
Suomi
Français
Frysk
Galego
ქართული
Deutsch
Ελληνικά
ગુજરાતી
Kreyol ayisyen
Harshen Hausa
Ōlelo Hawaiʻi
עִבְרִית
हिन्दी
Hmong
Magyar
Íslenska
Igbo
Bahasa Indonesia
Gaelige
Italiano
日本語
Basa Jawa
ಕನ್ನಡ
Қазақ тілі
ភាសាខ្មែរ
한국어
كوردی
Кыргызча
ພາສາລາວ
Latin
Latviešu valoda
Lietuvių kalba
Lëtzebuergesch
Македонски јазик
Malagasy
Bahasa Melayu
മലയാളം
Maltese
Te Reo Māori
मराठी
Монгол
ဗမာစာ
नेपाली
Norsk bokmål
پښتو
فارسی
Polski
Português
ਪੰਜਾਬੀ
Română
Русский
Samoan
Gàidhlig
Српски језик
Sesotho
Shona
سنڌي
සිංහල
Slovenčina
Slovenščina
Afsoomaali
Español
Basa Sunda
Kiswahili
Svenska
Тоҷикӣ
தமிழ்
తెలుగు
ไทย
Türkçe
Українська
اردو
O‘zbekcha
Tiếng Việt
Cymraeg
isiXhosa
יידיש
Yorùbá
Zulu